at Benzinga.com (Jan 14, 2015)
Vivus (VVUS +9%) spikes to a year high on the back of the the FDA's approval of Arena...
Vivus (VVUS +9%) spikes to a year high on the back of the the FDA's approval of Arena Pharmaceuticals' (ARNA +38%) weight-loss drug Belviq. Regulators are set to make a decision on its Qnexa diet drug on July 17.
From other sites
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 30, 2014)
at Zacks.com (Dec 8, 2014)
at CNBC.com (Dec 2, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs